Lexaria Bioscience Corp. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Commitments, Significant Contracts and Contingencies (Tables)

Commitments, Significant Contracts and Contingencies (Tables)

9 Months Ended

May 31, 2023

Commitments, Significant Contracts and Contingencies

Schedule of operating lease liabilities

2023 (three-months remaining)		$	11,204
2024			35,840
2025			37,094
2026			37,345
Thereafter			84,026
Total lease payments		$	205,509
Less: imputed interest			(30,605	)
Present value of operating lease liabilities		$	174,904
Less: current obligations under leases			(32,317	)
Total		$	142,587

Schedule of maturities of operating lease liabilities

		May 31, 2023				August 31, 2022
Right of use assets - operating leases		$	52,444			$	91,041
Remeasurement related to lease extension			156,565
Amortization			(30,882	)			(38,597	)
Total lease assets		$	178,127			$	52,444

Liabilities:		$	49,989			$	89,393
Remeasurement related to lease extension			156,565
Lease payments			(33,610	)			(44,600	)
Interest accretion			1,961				5,195
Total lease liabilities		$	174,905			$	49,988

Operating lease cost		$	178,127			$	52,444
Operating cash flows for lease		$	33,610			$	44,599
Remaining lease term			5.42 Years				1.17 Years
Discount rate			7.25	%			7.25	%